Main Content

CGCI

Program Description

The CGCI program included comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors, including HIV-associated lung cancer. This project has been a joint effort between the Office of Cancer Genomics (OCG) (now CCG) and the Office of HIV and AIDS Malignancy (OHAM). Its goals were to characterize HIV-associated cancers (obtained from HIV-infected patients) and compare them to the same types of cancers from patients without HIV infection.

HIV+ Tumor Molecular Characterization Project: Lung Cancer

Program Description

The CGCI program included comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors, including HIV-associated lung cancer. This project has been a joint effort between the Office of Cancer Genomics (OCG) (now CCG) and the Office of HIV and AIDS Malignancy (OHAM). Its goals were to characterize HIV-associated cancers (obtained from HIV-infected patients) and compare them to the same types of cancers from patients without HIV infection.

CGCI Non-Hodgkin Lymphoma (CGCI-NHL)

Program Description

The CGCI program includes comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. The CGCI-NHL study characterized B-cell non-Hodgkin lymphomas including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma

Blood. Volume 119, Issue 21: p. 4949-4952, 12 May 2012
10.1182/blood-2012-02-414441

Recently, the landscape of single base mutations in diffuse large B-cell lymphoma (DLBCL) was described. Here we report the discovery of a gene fusion between TBL1XR1 and TP63, the only recurrent somatic novel gene fusion identified in our analysis of transcriptome data from 96 DLBCL cases.

Analysis of FOXO1 mutations in diffuse large B-cell lymphoma

Blood. Volume 121, Issue 18: p. 3666-3674, 2 May 2013

10.1182/blood-2013-01-479865

Diffuse large B-cell lymphoma (DLBCL) accounts for 30% to 40% of newly diagnosed lymphomas and has an overall cure rate of approximately 60%. Previously, we observed FOXO1 mutations in non-Hodgkin lymphoma patient samples. To explore the effects of FOXO1 mutations, we assessed FOXO1 status in 279 DLBCL patient samples and 22 DLBCL-derived cell lines.

Subscribe to CGCI